Affymax Inc., of Palo Alto, Calif., appointed Robert Naso executive vice president of research and development, Gene Tutwiler executive vice president of new ventures and Mary Cirtin Fermi senior director of commercial development.
AnorMED Inc., of Vancouver, British Columbia, appointed Felix Baker to its board.
Archemix Corp., of Cambridge, Mass., appointed Larry Gold to its scientific advisory board.
Auxeris Therapeutics Inc., of St. Louis, appointed Jonathan McIntyre chief of development technology and operations.
BioAlliance Pharma, of Paris, appointed Richard Keatinge vice president of business development.
BioPartners GmbH, of Zug, Switzerland, appointed Jean-Noel Treilles CEO.
BioTrove Inc., of Woburn, Mass., appointed Michael Olex vice president of manufacturing.
Callisto Pharmaceuticals Inc., of New York, appointed John Brancaccio to its board.
CeMines Inc., of Evergreen, Colo., appointed Roger Attick to its board.
Cepheid Inc., of Sunnyvale, Calif., elected David Persing and Mitchell Mroz to its board.
Cerus Corp., of Concord, Calif., appointed Drew Pardoll, James Allison, Nina Bhardwaj, Philip Greenberg, Elizabeth Jaffee and Daniel Portnoy to its scientific advisory board.
CliniGenetics SA, of Nimes, France, appointed Jeannette Fareh head of pharmacological and preclinical research.
Codexis Inc., of Redwood City, Calif., appointed Bernard Kelley to its board.